0001326190false00013261902022-09-292022-09-29

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 29, 2022

ALTIMMUNE, INC.

(Exact name of registrant as specified in its charter)

Delaware

 

001-32587

 

20-2726770

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

910 Clopper Road, Suite 201S

Gaithersburg, Maryland

20878

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number including area code: (240) 654-1450

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.0001 per share

ALT

The NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.07 Submission of Matters to a Vote of Security Holders.

On September 29, 2022, Altimmune, Inc. (the “Company”) held its 2022 Annual Meeting of Stockholders (the “2022 Annual Meeting”). As of August 12, 2022, the record date for the 2022 Annual Meeting, there were 49,024,358 shares of the Company’s common stock outstanding and entitled to vote at the 2022 Annual Meeting. A total of 36,609,662 shares of common stock were present or represented by proxy at the 2022 Annual Meeting, representing 74.68% of the issued and outstanding shares entitled to vote at the meeting, representing a quorum. The proposals voted upon and the final results of the vote were as follows:

Proposal No. 1: Election of Directors. The results were as follows:

    

Broker

Director

For

Withhold

Non-Votes

Mitchel Sayare, Ph.D.

23,901,926

 

101,662

 

12,606,074

Vipin K. Garg, Ph.D.

23,896,828

 

106,760

 

12,606,074

David J. Drutz, M.D.

19,939,625

 

4,063,963

 

12,606,074

John M. Gill

19,940,007

 

4,063,581

 

12,606,074

Philip L. Hodges

23,903,614

 

99,974

 

12,606,074

Diane Jorkasky, M.D.

23,903,684

 

99,904

 

12,606,074

Wayne Pisano

19,705,074

 

4,298,514

 

12,606,074

Klaus O. Schafer, M.D., MPH

 

23,902,014

 

101,574

 

12,606,074

Proposal No. 2: Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2022. The results were as follows:

For

Against

Abstain

36,417,212

103,172

 

89,278

Proposal No. 3: Advisory vote on the Compensation of the Company’s named executive officers as disclosed in the Proxy Statement pursuant to the SEC’s compensation rules (referred to as the “say-on-pay” proposal). The results were as follows:

For

Against

Abstain

Broker Non-Votes

17,483,146

6,452,469

67,973

 

12,606,074

Proposal No. 4: Vote to authorize the adjournment of the 2022 Annual Meeting to enable the Board of Directors to solicit additional proxies. The results were as follows:

For

Against

Abstain

26,130,153

10,300,107

 

179,402

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALTIMMUNE, INC.

By:

 

/s/ Richard Eisenstadt

 

Name: Richard Eisenstadt

 

Title: Chief Financial Officer

Dated: September 29, 2022